Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Return Of Anti-commercial Bribery Campaign In China Could Benefit Big Companies And Blacklist Others

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Last month, China's Ministry of Health released a notice urging local health authorities to crack down on kickbacks to doctors in return for sales of pharmaceutical products under a policy that would ban drug manufacturers from participating in drug tenders in public hospitals for two years if they are blacklisted

You may also be interested in...

China Drug Pricing Reform Could Be In The Works At NDRC

The recent clampdown on commercial bribery, highlighted by the GSK case, and a new drug cost survey from NDRC could indicate drug pricing reform in China, experts say.

After Tender Comes Hospitals: China Mulls Restoring Second-Round Drug Price Negotiations

Banned two years ago, second-round drug price negotiations may be making a comeback in China, and the impact could be far-reaching for pharma companies.

China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit

SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts